EverPoint Asset Management’s Summit Therapeutics SMMT Stock Holding History

EverPoint Asset Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-55,111	Closed	-$376K	–	508
2016 Q1	$376K	Sell	55,111 -44,889	-45%	-$363K	0.01%	400
2015 Q4	$1.15M	Hold	100,000	–	–	0.02%	418
2015 Q3	$1.04M	Hold	100,000	–	–	0.03%	371
2015 Q2	$1.06M	Buy	+100,000	New	+$1.13M	0.02%	413

Other funds holding SMMT

LPU

Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

GPCM

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

EverPoint Asset Management's SMMT Position: Q2 2016 in Review

EverPoint Asset Management sold out of Summit Therapeutics (SMMT) in Q2 2016, closing a stake of 55,111 shares — an estimated $376K sold.

EverPoint Asset Management first reported a position in SMMT in Q2 2015 and held it in 4 quarters. The position peaked at $1.15M in Q4 2015. 11 funds tracked by Wall St. Rank hold SMMT as of Q2 2016.

EverPoint Asset Management reported no remaining Summit Therapeutics position as of Q2 2016 after selling out during the quarter.
EverPoint Asset Management sold 55,111 Summit Therapeutics shares in Q2 2016, an estimated $376K.
EverPoint Asset Management first reported a position in Summit Therapeutics in Q2 2015 and held it in 4 quarters.
EverPoint Asset Management's Summit Therapeutics position peaked at $1.15M in Q4 2015.
11 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2016.

Based on EverPoint Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.